Skip to main content
xMedica

NCT06956014ClinicalTrials.gov

Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy

Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of the Full-spectrum Cannabis Extract VER-01 in Participants With Chronic Painful Lumbosacral Radiculopathy

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

The aim of the trial is to prove the efficacy and safety of VER-01 compared to placebo in patients with chronic painful lumbosacral radiculopathy (PLSR) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not…

Phase 3810 participants sought43 sites1 country

Categories

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2025-05-02; recorded start 2026-09-22
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 2 other studies in this databaseCounted from the lead sponsor named in the record (Vertanical GmbH)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre0/8

    Single site, or site count not stated

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 810 participants (target), run at 43 sites.

How this score is built
  • Enrolment29/40

    810 participants (target)

  • Site count0/25

    Site count not stated in the record

  • Country count0/15

    Country count not stated in the record

  • Planned duration7/10

    Planned over about 24 months

  • Sponsor scale1/10

    Vertanical GmbH has led 3 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

The aim of the trial is to prove the efficacy and safety of VER-01 compared to placebo in patients with chronic painful lumbosacral radiculopathy (PLSR) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

Conditions

  • Lumbosacral Radiculopathy

Eligibility

Eligibility
SexAll
Ages18 Years – No maximum
Healthy volunteersNo

Eligibility as written in the registry

Inclusion Criteria: * Participants ≥ 18 years of age, all sexes * Participant voluntarily provided written informed consent * Participant is willing and able to comply with scheduled visits, treatment plan, eDiary, and other trial-related procedures throughout trial participation Exclusion Criteria: * Pregnant or breastfeeding female patients * Known history of previous or current severe psychiatric disorder as per DSM-5 (e.g., schizophrenia, bipolar disorder, severe anxiety disorder, psychotic disorder, post-traumatic stress disorder), or currently taking antipsychotic medication * Cardiovascular event or clinically significant cardiac dysfunction (e.g., congestive heart failure, myocardial ischemia, arrhythmias, poorly controlled high blood pressure, congenital long QT syndrome) within 12 months or a cardiac disorder that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study typeInterventional
PhasePhase 3
AllocationRandomised
Intervention modelPARALLEL
Primary purposeTREATMENT
MaskingQUADRUPLE (4)
Enrolment810 participants sought

Sponsor and collaborators

  • Vertanical GmbH Sponsor

Arms and interventions

  • VER-01 Dose 1EXPERIMENTAL
  • VER-01 Dose 2EXPERIMENTAL
  • PlaceboPLACEBO_COMPARATOR

Interventions

  • Other Placebo

    Comparator without active ingredient

  • Drug VER-01

    Standardized soft extract from Cannabis sativa DKJ127 L., cannabis flos (Cannabis flower), corresponding to 19 mg Δ9-Tetrahydrocannabinol (THC) per ml drug product

Outcome measures

  1. Primary outcome

    Efficacy based on pain reduction

    The primary endpoint is the absolute change in mean leg pain intensity in the index leg measured on an 11-point numerical rating scale (NRS) at Treatment Week 12 compared to Baseline.

    Time frame From Baseline to Treatment Week 12

Dates

Dates
Start dateSeptember 22, 2026 (actual)
Primary completionSeptember 1, 2028 (estimated)
CompletionSeptember 1, 2028 (estimated)
First postedMay 2, 2025 (actual)
Last updatedNovember 19, 2026
Results postedNot stated in the registry record
Status last verifiedNovember 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

43 sites are recruiting

United States

United States
FacilityCityState or regionStatus
Central Texas Clinical Research, LLCAustinTexasRecruiting
Boston Clinical TrialsBostonMassachusettsRecruiting
Bradenton Research CenterBradentonFloridaRecruiting
DFW Clinical TrialsCarrolltonTexasRecruiting
Epic Medical Research - CarroltonCarrolltonTexasRecruiting
Clinitiative - Clinical Trials of South Carolina - CharlestonCharlestonSouth CarolinaRecruiting
Epic Medical Research - ChickashaChickashaOklahomaRecruiting
Velocity Clinical Research - ClevelandClevelandOhioRecruiting
Epic Medical Research - DeSotoDeSotoTexasRecruiting
Mountain View Clinical ResearchDenverColoradoRecruiting
Innovare Research Group IFriendswoodTexasRecruiting
AGA Clinical TrialsHialeahFloridaRecruiting
HD Research - Memorial Hermann VillageHoustonTexasRecruiting
Perfizien Clinical Research LLCHoustonTexasRecruiting
Synergy Groups Medical - Southeast HoustonHoustonTexasRecruiting
Green Leaf Clinical TrialsJacksonvilleFloridaRecruiting
R & H Clinical ResearchKatyTexasRecruiting
Alliance for Multispecialty Research - KnoxvilleKnoxvilleTennesseeRecruiting
Epic Clinical Research - LewisvilleLewisvilleTexasRecruiting
Central Medical Research InstituteLong BeachCaliforniaRecruiting
Tekton Research - LongmontLongmontColoradoRecruiting
K2 Medical Research - Maitland IIMaitlandFloridaRecruiting
Velocity Clinical Research - MedfordMedfordOregonRecruiting
Alma Clinical ResearchMiamiFloridaRecruiting
Floridian Research Institute LLC IMiamiFloridaRecruiting
AMR MobileMobileAlabamaRecruiting
Monroe Biomedical Research - MonroeMonroeNorth CarolinaRecruiting
Alliance for Multispecialty Research - NorfolkNorfolkVirginiaRecruiting
Conquest Research - Lake NonaOrlandoFloridaRecruiting
Alfa Medical Research - Pembroke PinesPembroke PinesFloridaRecruiting
Flourish Research - PhiladelphiaPlymouth MeetingPennsylvaniaRecruiting
United Medical ResearchPort OrangeFloridaRecruiting
Boeson ResearchProvoUtahRecruiting
CenExel JBR - Salt Lake CitySalt Lake CityUtahRecruiting
Elixia Clinical Research CollaborativeSpringfieldMassachusettsRecruiting
Professional Health Care of PinellasSt. PetersburgFloridaRecruiting
Velocity Clinical Research - SuffolkSuffolkVirginiaRecruiting
Alliance for Multispecialty Research - Tempe ITempeArizonaRecruiting
Alliance for Multispecialty Research - Wichita EastWichitaKansasRecruiting
Grayline Research CenterWichita FallsTexasRecruiting
Progressive Medicine of the Triad, LLCWinston-SalemNorth CarolinaRecruiting
Conquest Research - Winter ParkWinter ParkFloridaRecruiting
Vitalix ClinicalWorcesterMassachusettsRecruiting

Study documents

No documents are linked in this registry record.

Changes over time

  1. November 19, 2026

    Site added

    11 sites added (43 total)

    3243

  2. November 2, 2026

    Site added

    9 sites added (32 total)

    2332

  3. October 21, 2026

    Site added

    1 site added (23 total)

    2223

  4. October 19, 2026

    Site added

    21 sites added (22 total)

    122

  5. September 28, 2026

    Status changed

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  6. September 28, 2026

    Site added

    1 site added (1 total)

    01

  7. September 28, 2026

    Recruitment opened

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING